Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma.
CAR T cells
immunotherapy
sarcoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Sep 2021
20 Sep 2021
Historique:
received:
23
08
2021
revised:
15
09
2021
accepted:
15
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Sarcomas are a diverse group of bone and soft tissue tumors that account for over 10% of childhood cancers. Outcomes are particularly poor for children with refractory, relapsed, or metastatic disease. Chimeric antigen receptor T (CAR T) cells are an exciting form of adoptive cell therapy that potentially offers new hope for these children. In early trials, promising outcomes have been achieved in some pediatric patients with sarcoma. However, many children do not derive benefit despite significant expression of the targeted tumor antigen. The success of CAR T cell therapy in sarcomas and other solid tumors is limited by the immunosuppressive tumor microenvironment (TME). In this review, we provide an update of the CAR T cell therapies that are currently being tested in pediatric sarcoma clinical trials, including those targeting tumors that express HER2, NY-ESO, GD2, EGFR, GPC3, B7-H3, and MAGE-A4. We also outline promising new CAR T cells that are in pre-clinical development. Finally, we discuss strategies that are being used to overcome tumor-mediated immunosuppression in solid tumors; these strategies have the potential to improve clinical outcomes of CAR T cell therapy for children with sarcoma.
Identifiants
pubmed: 34572932
pii: cancers13184704
doi: 10.3390/cancers13184704
pmc: PMC8465026
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Front Immunol. 2018 Nov 13;9:2629
pubmed: 30483271
J Clin Invest. 2021 Aug 16;131(16):
pubmed: 34396987
Lancet Oncol. 2017 Jun;18(6):719-731
pubmed: 28410997
Front Immunol. 2018 Oct 08;9:2250
pubmed: 30349530
Blood. 2012 Nov 29;120(23):4533-43
pubmed: 22936666
Front Immunol. 2020 May 15;11:940
pubmed: 32499786
Front Immunol. 2019 Feb 05;10:128
pubmed: 30804938
Trends Immunol. 2016 Mar;37(3):193-207
pubmed: 26839260
Mol Ther. 2017 Oct 4;25(10):2245-2253
pubmed: 28803861
Cancer Gene Ther. 2004 May;11(5):371-9
pubmed: 15060573
Front Oncol. 2019 Feb 26;9:69
pubmed: 30863720
Lancet. 2017 Dec 9;390(10112):2569-2582
pubmed: 28890157
Curr Treat Options Oncol. 2018 Mar 7;19(2):13
pubmed: 29516254
Cells. 2021 Apr 17;10(4):
pubmed: 33920505
Pediatr Blood Cancer. 2016 Oct;63(10):1780-5
pubmed: 27304202
Biomed Pharmacother. 2020 Jan;121:109625
pubmed: 31733578
Cells. 2020 Feb 27;9(3):
pubmed: 32121014
CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103
pubmed: 24488779
Cancers (Basel). 2020 Nov 10;12(11):
pubmed: 33182650
PLoS One. 2015 Jul 14;10(7):e0133152
pubmed: 26173023
J Clin Oncol. 2011 Mar 1;29(7):917-24
pubmed: 21282551
Clin Cancer Res. 2017 Oct 1;23(19):5824-5835
pubmed: 28659311
Blood. 2020 Sep 17;136(12):1407-1418
pubmed: 32483603
Clin Cancer Res. 2015 Mar 1;21(5):1019-27
pubmed: 25538264
Clin Cancer Res. 2012 Oct 1;18(19):5341-51
pubmed: 22879388
Cancer Res. 2006 Jan 1;66(1):24-8
pubmed: 16397210
Clin Sarcoma Res. 2015 Jan 24;5(1):4
pubmed: 25642322
J Clin Oncol. 2015 Jul 10;33(20):2279-87
pubmed: 26033801
Expert Opin Biol Ther. 2020 May;20(5):503-516
pubmed: 32125191
Nat Med. 2001 Jun;7(6):673-9
pubmed: 11385503
Cells. 2019 Dec 23;9(1):
pubmed: 31878087
Mol Med Rep. 2018 Feb;17(2):2083-2088
pubmed: 29207115
Nat Commun. 2019 Sep 11;10(1):4109
pubmed: 31511513
Int J Cancer. 2020 Jun 1;146(11):3184-3195
pubmed: 31621900
Cancer Discov. 2016 Mar;6(3):270-85
pubmed: 26715645
Am J Cancer Res. 2020 Feb 01;10(2):674-687
pubmed: 32195035
Cancer Gene Ther. 2021 Apr;28(3-4):321-334
pubmed: 32873870
J Hematol Oncol. 2018 Apr 23;11(1):58
pubmed: 29685162
Front Oncol. 2021 Jun 21;11:694941
pubmed: 34235085
Cancer Discov. 2018 Aug;8(8):944-957
pubmed: 29891538
Mol Ther. 2010 Apr;18(4):843-51
pubmed: 20179677
Hum Gene Ther. 2019 Apr;30(4):446-458
pubmed: 29706119
J Clin Invest. 2020 Jul 1;130(7):3391-3402
pubmed: 32538896
Eur J Cancer. 2005 Jun;41(9):1349-61
pubmed: 15913990
Cell Mol Immunol. 2010 Mar;7(2):157-62
pubmed: 20140010
Nat Rev Drug Discov. 2014 May;13(5):379-95
pubmed: 24751819
Cancer Immunol Res. 2018 Sep;6(9):990-1000
pubmed: 30181337
Cancer Res. 2016 Apr 15;76(8):2125-36
pubmed: 26880800
PLoS One. 2013 Aug 05;8(8):e70689
pubmed: 23940627
Ther Adv Hematol. 2019 Apr 15;10:2040620719841581
pubmed: 31019670
Annu Rev Immunol. 1995;13:251-76
pubmed: 7612223
Cancer Res. 2001 May 15;61(10):4048-54
pubmed: 11358824
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Cancer. 2021 Jul 26;:
pubmed: 34308557
Nature. 2016 Nov 17;539(7629):437-442
pubmed: 27642729
Nat Mater. 2012 Oct;11(10):895-905
pubmed: 22797827
Leukemia. 2015 Feb;29(2):415-22
pubmed: 25005243
Cancer Res. 2012 Jan 1;72(1):271-81
pubmed: 22075555
Cancer Immunol Immunother. 2015 Oct;64(10):1241-50
pubmed: 26105626
J Mol Cell Biol. 2012 Oct;4(5):341-3
pubmed: 22831835
Cancer Cell. 2021 Feb 8;39(2):193-208.e10
pubmed: 33357452
Ann Oncol. 2021 Aug 8;:
pubmed: 34375680
Front Oncol. 2020 Jul 07;10:1000
pubmed: 32733795
Oncoimmunology. 2017 Jan 17;6(2):e1273301
pubmed: 28344885
Cancer Cell. 2013 Nov 11;24(5):589-602
pubmed: 24209604
J Hematol Oncol. 2021 Mar 19;14(1):45
pubmed: 33741032
Clin Cancer Res. 2013 Oct 15;19(20):5636-46
pubmed: 23873688
J Clin Invest. 2020 Feb 3;130(2):673-685
pubmed: 31845905
Am J Hematol. 2018 Jul;93(7):851-858
pubmed: 29633386
Curr Oncol Rep. 2018 Aug 1;20(9):73
pubmed: 30069644
Mol Ther. 2018 Jul 5;26(7):1855-1866
pubmed: 29807781
Cancer Discov. 2018 Aug;8(8):914-917
pubmed: 30076141
J Immunother Cancer. 2015 Aug 18;3:35
pubmed: 26286851
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Chin Clin Oncol. 2018 Aug;7(4):44
pubmed: 30173534
Cancer. 2017 Oct 1;123(19):3807-3815
pubmed: 28608950
Cancer Discov. 2019 Nov;9(11):1511-1519
pubmed: 31527131
Cancer. 2016 Apr 1;122(7):1009-16
pubmed: 26848927
Hum Pathol. 2007 Aug;38(8):1184-91
pubmed: 17509661
Sci Rep. 2017 Apr 7;7(1):737
pubmed: 28389661
PLoS One. 2012;7(2):e31210
pubmed: 22355347
Cancer. 2020 May 1;126 Suppl 9:2093-2100
pubmed: 32293729
Biochim Biophys Acta. 2014 Apr;1845(2):266-76
pubmed: 24582852
Nat Commun. 2020 Jul 15;11(1):3549
pubmed: 32669548
Nat Commun. 2019 Sep 3;10(1):3974
pubmed: 31481662
Clin Cancer Res. 2019 Feb 1;25(3):1098-1112
pubmed: 30352904
Cell Res. 2020 Aug;30(8):660-669
pubmed: 32467592
Nat Commun. 2020 Dec 10;11(1):6322
pubmed: 33303760
J Clin Oncol. 2015 Sep 20;33(27):3036-46
pubmed: 26304893
Haematologica. 2020 Jan 31;105(2):e76-e79
pubmed: 31171645
J Clin Oncol. 2015 May 20;33(15):1688-96
pubmed: 25800760
Eur J Immunol. 2004 Feb;34(2):336-44
pubmed: 14768038
Am J Pathol. 2013 Jun;182(6):2121-31
pubmed: 23562272
Clin Cancer Res. 2019 Apr 15;25(8):2560-2574
pubmed: 30655315
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50
pubmed: 24127572
Eur J Surg Oncol. 2006 May;32(4):466-8
pubmed: 16524687
Cell Rep. 2017 Sep 26;20(13):3025-3033
pubmed: 28954221
Annu Rev Immunol. 2001;19:423-74
pubmed: 11244043
J Immunother Cancer. 2019 Oct 24;7(1):276
pubmed: 31651363
J Clin Invest. 2016 Sep 1;126(9):3479-94
pubmed: 27548527
Nat Rev Clin Oncol. 2020 Mar;17(3):147-167
pubmed: 31848460
Mol Carcinog. 2018 Nov;57(11):1664-1671
pubmed: 30035346
J Hematol Oncol. 2019 Jul 16;12(1):78
pubmed: 31311607
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Blood. 2010 Apr 29;115(17):3508-19
pubmed: 20190192
Open Access Maced J Med Sci. 2018 Sep 04;6(9):1555-1560
pubmed: 30337965
Pediatr Blood Cancer. 2020 Oct;67(10):e28313
pubmed: 32729251